The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.
“Combination therapy with teclistamab plus talquetamab showed encouraging antitumor activity in a majority of patients with relapsed or refractory multiple myeloma,” Yael C. Cohen, MD, head of the myeloma unit at Tel Aviv Sourasky Medical Center, and colleagues wrote. “In this study, talquetamab plus teclistamab had a similar safety profile to each agent as monotherapy, although the observed